Compare TOI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOI | MYGN |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | United States | United States |
| Employees | 641 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.9M | 444.2M |
| IPO Year | N/A | 1996 |
| Metric | TOI | MYGN |
|---|---|---|
| Price | $5.28 | $4.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $6.67 | ★ $7.64 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $30.15 | $6.86 |
| Revenue Next Year | $25.77 | $5.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $2.02 | $3.53 |
| 52 Week High | $5.58 | $8.59 |
| Indicator | TOI | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 64.36 | 54.92 |
| Support Level | $2.91 | $4.31 |
| Resistance Level | $5.58 | $4.92 |
| Average True Range (ATR) | 0.40 | 0.30 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 77.49 | 67.30 |
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.